|
|
|
|
Vol. 58, Issue 6, 1581-1592, December 2000
Molecular Neurobiology Branch, National Institute on Drug Abuse,
Intramural Research Program, National Institutes of Health, Baltimore,
Maryland
Cocaine blocks the normal role of the dopamine transporter (DAT)
in terminating dopamine signaling and in restricting its spatial spread
through molecular interactions that remain largely obscure. Cocaine
analog structure-activity studies suggest roles for cationic and
hydrophobic interactions between DAT, dopamine, cocaine, and the sodium
and chloride ions whose gradients power uptake processes. Tryptophan
residues lying in putative DAT transmembrane domains could contribute
to both aromatic and cationic interactions between DAT and dopamine or
cocaine. We thus produced mutant DATs with alanine substitutions for
tryptophans lying in or near putative DAT transmembrane domains. We
have focused analyses on mutations that exert selective influences on
affinities for dopamine or the cocaine analog CFT
[(
)-2-
-carbomethoxy-3-
-(4-fluorophenyl)tropane]. Substitutions W162A, W255A, and W310A reduced dopamine uptake affinities. 5W266A, 12W555A, and 12W561A each reduced dopamine superficial recognition affinities by more than 3-fold and all retained
affinity for CFT. W406A, W496A and W523A each reduced CFT affinity, and
W84A increased CFT affinity. None of these four mutations decreased
dopamine uptake affinity. These data, current provisional DAT
structural models, and results from parallel studies of other mutants
identify candidate dopamine-selective DAT domains for transmembrane
dopamine permeation and regions in which mutations selectively lower
CFT affinities. Tryptophan residues may contribute more extensively to
these selective domains than other previously studied DAT amino acids.
These sites provide tempting targets for selective blockers of cocaine
recognition by DAT.
This article has been cited by other articles:
![]() |
Z. Lin and G. R. Uhl Dopamine Transporter Mutants with Cocaine Resistance and Normal Dopamine Uptake Provide Targets for Cocaine Antagonism Mol. Pharmacol., April 1, 2002; 61(4): 885 - 891. [Abstract] [Full Text] [PDF] |
||||